The future direction of the US Department of Health & Human Services (HHS) under Robert F. Kennedy, Jr. was a worry for many pharmaceutical executives at the J.P. Morgan Healthcare Conference. Vaccine manufacturers, in particular, are preparing to push back against a wave of disinformation about the safety and efficacy of vaccines, given that Kennedy has espoused anti-vaccine rhetoric in the past.
Vaccine Manufacturers Prepare To Fight Disinformation With Transparency
At J.P. Morgan, GSK, Sanofi and Pfizer said they are prepared to address questions about vaccines under a new US administration, while former FDA commissioner Gottlieb warned of threats to public safety.
More from J.P. Morgan
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.